Haleos Labs Subsidiary Clears USFDA Inspection With Zero Observations

Haleos Labs Ltd announced that its material subsidiary, Mahi Drugs Private Limited, successfully concluded a USFDA inspection of its API manufacturing facility. The inspection, held from September 15-18, 2026, resulted in zero Form 483 observations, mirroring the outcome of a previous inspection in January 2025. This achievement underscores the company's commitment to stringent regulatory compliance, quality, and operational excellence. The facility is located in Jawaharlal Nehru Pharma City, parawada, Anakapalli, Andhra Pradesh.